National Cooperative Drug Discovery Groups for the Treatment of Mood Disorders or Nicotine Addiction (Ncddg-Md/Na)

The summary for the National Cooperative Drug Discovery Groups for the Treatment of Mood Disorders or Nicotine Addiction (Ncddg-Md/Na) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
National Cooperative Drug Discovery Groups for the Treatment of Mood Disorders or Nicotine Addiction (Ncddg-Md/Na): The intent of this solicitation is to invite applications from academic and pharmaceutical industry investigators interested in participating with National Institute of Mental Health (NIMH) and the National Institute on Drug Abuse (NIDA) in a National Cooperative Drug Discovery Group (NCDDG-MD/NA) Program to accelerate innovative drug discovery, the development of pharmacologic tools for basic and clinical research in mood disorders or nicotine addiction, and, in the case of mood disorders, the development and validation of models for evaluating novel therapeutics. NIMH and NIDA are interested in jointly advancing the discovery of new ligands because we anticipate that there are targets in common and overlap in the expertise that can be brought to bear. The goal of the NCDDG-MD/NA Program is to establish long-term partnerships between NIH, academia, and industry that will advance the development and testing of fundamentally new, rationally designed medications and treatments for mental disorders and nicotine addiction. Academic and/or pharmaceutical industry components of each NCDDG-MD/NA should contribute unique scientific expertise towards the common goal of translating basic science findings into innovative pharmacologic treatments for mental disorders and drug addiction. Each partnership or group must consist of a multi- disciplinary team of scientists with appropriate expertise to address the development and evaluation of novel ligands, and the development of testing models where required. Scientists from both academia and pharmaceutical industry are encouraged to participate within an NCDDG-MD/NA. Scientists from foreign institutions and NIH Intramural laboratories may participate in some aspects, as noted in other sections of this application. The NCDDG-MD/NA Program is most appropriate for applications that include collaborations, Research Projects or core components from academia and the private sector (e.g., pharmaceutical, chemical, or biotechnological companies). It is anticipated that the interaction of academic and non-profit research institutions with industry and NIH via the NCDDG-MD/NA model will: 1) accelerate the discovery of new therapeutics for mood disorders and nicotine addiction; 2) increase the availability of pharmacologic research tools for basic and clinical research; and 3) facilitate the development and validation of models to evaluate novel therapeutics in mood disorders. Small businesses without academic and/or industry partners are encouraged to respond to parallel Program Announcements: Pharmacologic Agents and Drugs for Mental Disorders (SBIR Award) http://grants.nih.gov/grants/guide/pa-files/PA-02-027.html], Development of PET and SPECT Ligands for Brain Imaging (SBIR Award) [http://grants.nih.gov/grants/guide/pa-files/PA-02-028.html], and Innovative Toxicology Models: SBIR/STTR - Addendum to PA-02-075, Notice NOT-MH-02-005 [http://grants.nih.gov/grants/guide/notice-files/NOT-MH-02-005.html].
Federal Grant Title: National Cooperative Drug Discovery Groups for the Treatment of Mood Disorders or Nicotine Addiction (Ncddg-Md/Na)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-MH-03-008
Type of Funding: Grant
CFDA Numbers: 93.24293.279
CFDA Descriptions: Mental Health Research Grants 93.279 Drug Abuse Research Programs
Current Application Deadline: No deadline provided
Original Application Deadline: Nov 26, 2002
Posted Date: Sep 04, 2002
Creation Date: Dec 26, 2002
Archive Date: Dec 26, 2002
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Individuals For profit organizations other than small businesses Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification)
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [email protected] NIH OER Webmaster